Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%77 3-Year Book Growth Rate is 6.90% as of Dec. 2025, which is 39% below its 10-year median of 11.30. GuruFocus rates SHTDF with a GF Score™ of 77/100 and a GF Value™ of $2.66 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 110 Medical Distribution companies, Sinopharm Group Co ranks better than 72.73% on this metric.
During the past 12 months, Sinopharm Group Co's average Book Value per Share Growth Rate was 10.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 6.90% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 6.00% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 9.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Sinopharm Group Co was 77.30% per year. The lowest was 3.60% per year. And the median was 11.30% per year.
Sinopharm Group Co (OTCPK:SHTDF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Sinopharm Group Co 3-Year Book Growth Rate Related Terms
SHTDF vs MCK, CAH, COR: 3-Year Book Growth Rate Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co 3-Year Book Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's 3-Year Book Growth Rate falls into.
Sinopharm Group Co 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 6.90% mean?
Sinopharm Group Co (SHTDF) has a 3-Year Book Growth Rate of 6.90% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Sinopharm Group Co and its competitors. This is 39% below median its historical median of 11.30. Over the past decade, Sinopharm Group Co's 3-Year Book Growth Rate has ranged from 3.60 to 77.30. According to the industry distribution chart, Sinopharm Group Co ranks #30 out of 110 companies in the Medical Distribution industry, placing it in the top 27.3%.
Is Sinopharm Group Co's 3-Year Book Growth Rate too high?
Sinopharm Group Co's current 3-Year Book Growth Rate of 6.90% is 39% below median its 10-year median of 11.30. Over the past 10 years, this metric has ranged from a low of 3.60 to a high of 77.30. The Medical Distribution industry median 3-Year Book Growth Rate is 3.15. Sinopharm Group Co's value of 6.90% is 119% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #30 out of 110 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's 3-Year Book Growth Rate compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #30 out of 110 companies for 3-Year Book Growth Rate. This puts Sinopharm Group Co in the upper half of its industry. The industry median 3-Year Book Growth Rate is 3.15. Sinopharm Group Co's value of 6.90% is 119% above this benchmark. Historically, Sinopharm Group Co's own 3-Year Book Growth Rate has ranged from 3.60 to 77.30 over the past decade. While the company's 10-year median is 11.30 vs. the industry median of 3.15, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Distribution company?
The median 3-Year Book Growth Rate among Medical Distribution companies is 3.15, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current 3-Year Book Growth Rate of 6.90% is 119% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median 3-Year Book Growth Rate is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current 3-Year Book Growth Rate is 6.90%, which is 39% below median its own 10-year median of 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.66, compared to a current price of $2.13 — trading 19.8% below its estimated fair value. The current 3-Year Book Growth Rate is 6.90%, which is 39% below median its 10-year median of 11.30 and 119% above the Medical Distribution industry median of 3.15. Sinopharm Group Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current 3-Year Book Growth Rate is 6.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 19.8% below its estimated GF Value™ of $2.66.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
3-Year Book Growth Rate: 6.90% (39% below median its 10-year median of 11.30)
GF Value™: $2.66 vs. price of $2.13 (19.8% below fair value)
Industry Position: 119% above the Medical Distribution median (#30 of 110)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
77GF Score
Get the complete analysis for SHTDF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
